Seminars in Oncology
Volume 31, Issue 1 , Pages 27-32 , February 2004

Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin’s disease: indications and results

  • Norbert Schmitz

      Affiliations

    • Department of Hematology, AK St. Georg, Hamburg, Germany
    • Corresponding Author InformationAddress reprint requests to Norbert Schmitz, MD, PhD, Department of Hematology, AK St. Georg, Lohmühlenstr. 5, D-20099, Hamburg, Germany
    • ,
  • Anna Sureda

      Affiliations

    • Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Stephen Robinson

      Affiliations

    • Department of Hematology, University College Hospital, London, United Kingdom, UK

References 

  1. Diehl V, Franklin J, Hasenclever D, et al.  BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma (Interim report from a trial of the Germany Hodgkin’s Lymphoma Study Group). J Clin Oncol. 1998;16:3810–3821
  2. Horning SJ, Williams J, Bartlett NL, et al.  Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease (Eastern Cooperative Oncology Group Pilot Study E1492). J Clin Oncol. 2000;18:972–980
  3. Lohri A, Barnett M, Fairey RN, et al.  Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy (Identification of risk factors from the British Columbia experience 1970 to 1988). Blood. 1991;77:2292–2298
  4. Josting A, Franklin J, May M, et al.  New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2002;20:221–230
  5. Bonfante V, Santoro A, Viviani S, et al.  G. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528–534
  6. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med. 1982;96:139–144
  7. Longo DL, Duffey PL, Young RC, et al.  Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy (The low probability for cure). J Clin Oncol. 1992;10:210–218
  8. Colwill R, Crump M, Couture F, et al.  Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396–402
  9. Pfreundschuh MG, Rueffer U, Lathan B, et al.  Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens (A trial of the German Hodgkin’s Disease Study Group). J Clin Oncol. 1994;12:580–586
  10. Velasquez WS, Cabanillas F, Salvador P, et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  11. Moskowitz CH, Nimer SD, Zelenetz AD, et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’ disease (Analysis by intent to treat and development of a prognostic model). Blood. 2001;97:616–623
  12. Linch DC, Winfield D, Goldstone AH, et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease (Results of a BNLI randomised trial). Lancet. 1993;341:1051–1054
  13. Schmitz N, Pfistner B, Sextro M, et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy requiring autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease. Lancet. 2002;359:2065–2071
  14. Josting A, Reiser M, Rueffer U, et al.  Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma (Is there a chance for cure?). J Clin Oncol. 2000;18:332–339
  15. Sweetenham JW, Carella AM, Taghipour G, et al.  High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy (Results in 175 patients reported to the European Group for Blood and Marrow Transplantation). J Clin Oncol. 1999;17:3101–3109
  16. Lazarus HM, Rowlings PhA, Zhang MJ, et al.  Autotransplants for Hodgkin’s disease in patients never achieving remission (A report from the autologous blood and marrow transplant Registry). J Clin Oncol. 1999;17:534–545
  17. Sureda A, Arranz R, Iriondo A, et al.  Autologous stem cell transplantation for Hodgkin’s disease (Results and prognostic factors in 494 patients from the Group Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group). J Clin Oncol. 2001;19:1395–1404
  18. Lazarus HM, Loberiza FR, Zhang MJ, et al.  Autotransplants for Hodgkin’s disease in first relapse or second remission (A report from the Autologous Blood and Marrow Transplant Registry (ABMTR)). Bone Marrow Transplant. 2001;27:387–396
  19. Horning SJ, Chao NJ, Negrin RS, et al.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease (Analysis of the Stanford University results and prognostic indices). Blood. 1997;89:801–813
  20. Fermé C, Bastion Y, Lepage E, et al.  The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol. 1995;6:543–549
  21. Brice P, Bouabdallah R, Moreau P, et al.  Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease (Analysis of 280 patients from the French registry). Bone Marrow Transplant. 1997;20:21–216
  22. Sweetenham JW, Taghipour G, Milligan D, et al.  High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy (Results from the EBMT). Bone Marrow Transplant. 1997;20:745–752
  23. Appelbaum FR, Sullivan KM, Thomas ED, et al.  Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s disease. J Clin Oncol. 1985;3:1490–1494
  24. Philipps GL, Reece DE, Barnett MJ, et al.  Allogeneic marrow transplantation for refractory Hodgkin’ disease. J Clin Oncol. 1989;7:1039–1045
  25. Anderson JE, Litzow MR, Appelbaum FR, et al.  Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease (The 21-year Seattle experience). J Clin Oncol. 1993;11:2342–2350
  26. Jones RJ, Ambinder RF, Piantadosi S, et al.  Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–653
  27. Weiden PL, Sullivan KM, Flournoy N, et al.  Antileukemic effect of chronic graft-versus-host disease. N Engl J Med. 1981;304:1529–1533
  28. Gajewski JL, Phillips GL, Sobocinski KA, et al.  Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–578
  29. Milpied N, Fielding AK, Pearce RM, et al.  Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol. 1996;14:1291–1296
  30. Akpek G, Ambinder RF, Piantadosi S, et al.  Long-term results of blood and marrow transplantation for Hodgkin’s disease. J Clin Oncol. 2001;19:4314–4321
  31. Storb R, Yu G, John L, et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  32. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft-versus-leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  33. Slavin S, Nagler A, Naparstek E, et al.  Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood. 1998;91:756–763
  34. Anderlini P, Giralt S, Andersson B, et al.  Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin’s disease. Bone Marrow Transplant. 2000;26:615–620
  35. Nagler A, Slavin S, Varadi G, et al.  Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:1021–1028
  36. Kottaridis PD, Milligan DW, Chopra R, et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  37. Carella AM, Cavaliere M, Lerma E, et al.  Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hemopoietic stem cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:3918–3924

PII: S0093-7754(03)00561-X

doi: 10.1053/j.seminoncol.2003.10.018

Seminars in Oncology
Volume 31, Issue 1 , Pages 27-32 , February 2004

Article Tools

* Image Usage & Resolution